Condition: Patients With Chemotherapy-Induced Thrombocytopenia · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
This description comes directly from the study's public registry record.
Junye Xiong · 0518-82342973 · junye.xiong.jx9@hengrui.com
Always discuss trial participation with your own doctor first.
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Not Yet Recruiting |
| AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology | Denver, Colorado, United States | Not Yet Recruiting |
| Oncology & Hematology Associates of West Broward | Coral Springs, Florida, United States | Not Yet Recruiting |
| Mid-Florida Hematology & Oncology Centers, P.A. | Orange City, Florida, United States | Recruiting |
| Springfield Clinic | Springfield, Illinois, United States | Not Yet Recruiting |
| Morristown Medical Center | Morristown, New Jersey, United States | Not Yet Recruiting |
| New York Cancer and Blood Specialists One Oncology | Shirley, New York, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07286032